Join +750K new investors every month who copy stock picks from billionaire's portfoliosSign Up Free

Regenxbio shares target raised to $39 by Baird on positive trial data

EditorNatashya Angelica
Published 06/03/2024, 08:44 am
© Reuters.
RGNX
-

On Tuesday, Regenxbio Inc. (NASDAQ:RGNX) saw its share price target increased by Baird from $34.00 to $39.00, while the firm reaffirmed its Outperform rating on the stock. The adjustment follows encouraging clinical trial results for the company's drug candidate RGX-202. A patient at the second dose level exhibited a 76% expression and a notable reduction in creatine kinase (CK), a muscle damage marker.

Baird's optimism stems from the belief that the higher dose level of RGX-202 could lead to more consistent responses in future larger-scale trials, without significantly raising safety concerns. These promising results have led to increased confidence in the drug's potential and its prospects for regulatory approval.

The analyst from Baird highlighted the significance of the recent trial outcomes, stating that the positive data from the first patient at the second dose level supports the notion that RGX-202 could be more effective at a higher dose. The lack of a substantial increase in safety risk is also a critical factor that underpins the raised price target.

The anticipation around Regenxbio's RGX-202 is mounting as the company is preparing to initiate a pivotal trial in the second half of 2024. Baird's updated price target reflects the heightened expectations for the drug's approval chances following the recent trial data.

Regenxbio's progress with RGX-202 comes at a crucial time as the company gears up for the next stages of clinical development. The raised share price target to $39 by Baird is a testament to the growing confidence in the drug's success and its potential impact on the market.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.